
1. malar j. 2017 sep 30;16(1):392. doi: 10.1186/s12936-017-2034-2.

measuring ex vivo drug susceptibility plasmodium vivax isolates cambodia.

chaorattanakawee s(1)(2), lon c(3), chann s(3), thay kh(4), kong n(4), y(4), 
sundrakes s(3), thamnurak c(3), chattrakarn s(3), praditpol c(3), yingyuen k(3), 
wojnarski m(3), huy r(4), spring md(3), walsh ds(3), patel jc(5), lin j(5),
juliano jj(5), lanteri ca(3), saunders dl(3)(6).

author information: 
(1)department immunology medicine, armed forces research institute of
medical science, bangkok, thailand. suwann67@yahoo.com.
(2)department parasitology entomology, faculty public health, mahidol
university, bangkok, thailand. suwann67@yahoo.com.
(3)department immunology medicine, armed forces research institute of
medical science, bangkok, thailand.
(4)national center parasitology, entomology malaria control, phnom penh, 
cambodia.
(5)division infectious diseases, school medicine, university north
carolina, chapel hill, nc, usa.
(6)us army medical materiel development activity, fort detrick, frederick, md,
usa.

background: intensive plasmodium falciparum multidrug resistance
surveillance continues cambodia, relatively little known plasmodium
vivax drug resistance cambodia elsewhere. investigate p. vivax
anti-malarial susceptibility cambodia, 76 fresh p. vivax isolates collected
from oddar meanchey (northern cambodia) 2013-2015 assessed ex vivo
drug susceptibility using microscopy-based schizont maturation test (smt) and
a plasmodium pan-species lactate dehydrogenase (pldh) elisa. p. vivax multidrug
resistance gene 1 (pvmdr1) mutations, copy number analysed subset
of isolates.
results: ex vivo testing interpretable 80% isolates using the
pldh-elisa, 25% smt. plasmodium vivax drug susceptibility by
pldh-elisa directly compared 58 p. falciparum isolates collected from
the locations 2013-4, tested histidine-rich protein-2 elisa. median
pldh-elisa ic50 p. vivax isolates significantly lower for
dihydroartemisinin (3.4 vs 6.3 nm), artesunate (3.2 vs 5.7 nm), chloroquine
(22.1 vs 103.8 nm) p. falciparum higher mefloquine (92 vs 66 nm).
there significant differences lumefantrine doxycycline. p.
vivax p. falciparum comparable median piperaquine ic50 (106.5 vs
123.8 nm), p. falciparum isolates able grow much higher
concentrations normal standard range used, attaining 100-fold
greater ic50s p. vivax. high percentage p. vivax isolates pvmdr1
y976f (78%) f1076l (83%) mutations none pvmdr1 amplification.
conclusion: findings high p. vivax ic50 mefloquine piperaquine, but
not chloroquine, suggest significant drug pressure drugs used treat
multidrug resistant p. falciparum cambodia. plasmodium vivax isolates are
frequently exposed mefloquine piperaquine due mixed infections 
long elimination half-life drugs. difficulty distinguishing infection
due relapsing hypnozoites versus blood-stage recrudescence complicates
clinical detection p. vivax resistance, well-validated molecular markers
of chloroquine resistance remain elusive. pldh assay may useful
adjunctive tool monitoring emerging drug resistance, though thorough
validation needed. given high grade clinical chloroquine resistance observed
recently neighbouring countries, low chloroquine ic50 values seen 
not interpreted susceptibility absence clinical data.
incorporating pldh monitoring therapeutic efficacy studies individuals
with p. vivax help validate field-expedient method.

doi: 10.1186/s12936-017-2034-2 
pmcid: pmc5622433
pmid: 28964258  [indexed medline]

